Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder

S Cervenka¹, E Hedman¹–², Y Ikoma¹–³, D Radu Djurfeldt¹, C Rück¹, C Halldin³ and N Lindefors¹

The dopamine system has been suggested to play a role in social anxiety disorder (SAD), partly based on molecular imaging studies showing reduced levels of striatal dopaminergic markers in patients compared with control subjects. However, the dopamine system has not been examined in frontal and limbic brain regions proposed to be central in the pathophysiology of SAD. In the present study, we hypothesized that extrastriatal dopamine D2-receptor (D2-R) levels measured using positron emission tomography (PET) would predict symptom reduction after cognitive behavior therapy (CBT). Nine SAD patients were examined using high-resolution PET and the high-affinity D2-R antagonist radioligand [¹¹C]FLB 457, before and after 15 weeks of CBT. Symptom levels were assessed using the anxiety subscale of Liebowitz Social Anxiety Scale (LSASanx). At posttreatment, there was a statistically significant reduction of social anxiety symptoms (P<0.005). Using a repeated measures analysis of covariance, significant effects for time and time × LSUAsanx change on D2-R-binding potential (BPND) were shown (P<0.05). In a subsequent region-by-region analysis, negative correlations between change in D2-R BPND and LSASanx change were found for medial prefrontal cortex and hippocampus (P<0.05). This is the first study to report a direct relationship between symptom change after psychological treatment and a marker of brain neurotransmission. Using an intra-individual comparison design, the study supports a role for the dopamine system in cortical and limbic brain regions in the pathophysiology of SAD.

Translational Psychiatry (2012) 2, e120; doi:10.1038/tp.2012.40; published online 22 May 2012

Introduction

The dopamine system is involved in social behavior, learning and emotional regulation, predicting a role in the pathophysiology of social anxiety disorder (SAD). Molecular imaging studies have provided preliminary support for this hypothesis, showing reduced levels of striatal dopaminergic markers both pre- and postsynaptically in patients compared with control subjects.¹–³ However, negative results have also been reported.⁴ A possible explanation for this inconsistency may be that none of the studies performed thus far have examined the dopamine system in limbic or prefrontal brain regions, which have shown to be involved in SAD based on brain activation studies (for a review, see ref. 5). In part, this has been due to methodological limitations, as the first generation D2-receptor (D2-R) positron emission tomography (PET) radioligands such as [¹¹C]raclopride have insufficient affinity for measurements in low-density extrastriatal brain regions.

PET studies have shown a marked inter-individual variability in levels of dopaminergic markers in healthy control subjects.⁵ This constitutes a drawback in studies where patients and control subjects are compared, as large sample sizes are needed in order to detect small differences. Furthermore, group differences in biomarker levels do not directly infer causal links to disease symptoms. An experimental design where the biological marker is observed as a function of change in disease state could be considered a more powerful strategy in these respects. In psychiatry, the development of effective forms of psychotherapy offers a unique opportunity to improve symptoms without directly interfering with brain biochemistry. For SAD, cognitive behavior therapy (CBT) leads to clinical improvement in up to 75% of patients.⁶,⁷

Although several studies have investigated the effect of psychotherapy on brain activation as assessed using PET and functional magnetic resonance imaging (fMRI), reports on changes in neurotransmission have been scarce. Increased binding to the serotonin transporter in the midbrain after 12 months of psychodynamic therapy was demonstrated in a subgroup of patients with depression. No change was shown in dopamine transporter levels.⁹ In a subsequent study using PET and [¹¹C]WAY-100635, SHT₁a-receptor binding was shown to increase in patients with major depressive disorder after brief psychodynamic psychotherapy.¹⁰ However, in neither of these studies a relationship could be shown between change in biomarker levels and symptom improve-

¹Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Stockholm, Sweden; ²Department of Clinical Neuroscience, Osher Center for Integrative Medicine and Division of Psychology, Karolinska Institutet, Stockholm, Sweden and ³Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

Correspondence: Dr S Cervenka, Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Karolinska University Hospital Solna, Building R5, 171 76 Stockholm, Sweden.

E-mail: simon.cervenka@ki.se

Keywords: CBT; dopamine; D2-receptor; PET; social anxiety disorder

Received 19 March 2012; accepted 10 April 2012
ment. Finally, in a recent study in patients with depression, no effect of psychodynamic psychotherapy was shown on dopamine D2-R binding in the striatum.11 To date, no studies have examined the effect of CBT on markers of brain neurotransmission. As CBT is an intensive treatment with emphasis on repeated exposure to feared stimuli in order to reduce anxiety levels (for example, see ref. 12), this form of psychotherapy could be a more promising venue for detecting neurobiological correlates to symptom change.

In the present study, the primary objective was to investigate the role of the dopamine system in SAD using an inter-individual comparison design, by examining the relationship between change in symptom levels after CBT and change in dopamine D2-R binding. We predicted that increased binding potential (BPND) would be associated specifically with reduced anxiety levels in social situations. The study was performed using the high-affinity D2-R antagonist radioligand [11C]FLB 457,13 which enables measurements in extrastriatal brain regions of particular interest for SAD, and examinations were conducted on an high-resolution research tomograph PET system for increased anatomical precision.14

Materials and methods

Subjects. Nine patients with SAD were recruited from a study comparing CBT administered via the Internet versus group therapy, the results of which have been reported elsewhere.15 As part of the treatment study, all subjects were interviewed by a senior psychiatrist and were found to fulfill DSM IV criteria for SAD 16 using the Structured Clinical Interview for DSM-IV axis I disorders. Comorbidity, including drug addiction and abuse, was assessed using the Mini-International Neuropsychiatric Interview.17 After inclusion in the PET study, patients were randomized to treatment either in group format or treatment via the Internet. Subjects were healthy as determined by a physical examination and routine blood tests as well as a brain MRI examination. Three patients received cognitive behavioral therapy based CBT and group CBT yield equivalent treatment effects.15 The median number of completed sessions or modules for both delivery formats was 13 of 15 (mean ± s.d.) weeks before pre-treatment ratings, and the time between post-treatment ratings and PET 2 was 17 ± 15 days.

Treatment. Three patients received cognitive behavioral group therapy12 and six patients Internet-based CBT.20 The duration of treatment was 15 weeks in both conditions. The treatment employed in the study, in both delivery formats, followed a CBT-model stressing the importance of avoidance and safety behaviors as well as misinterpretations of social events and internal focus as maintaining factors of SAD.21,22 The theoretical basis and proposed mechanisms were the same and the main finding from the treatment study, from which the present sample was recruited, was that Internet-based CBT and group CBT yield equivalent treatment effects.15 The median number of completed sessions or modules for both delivery formats was 13 of 15 (mean = 11.5; s.d. = 3.5). All participants were exposed to the main components of the treatment.

MR examinations. As part of the inclusion process, all patients performed a T1- and T2-weighted MRI examination using a 1.5T GE Signa Scanner (Milwaukee, WI, USA). The T2 image was inspected for macroscopic pathology, and the T1 image was used for the subsequent image analysis.

Radiochemistry. The radioligand [11C]FLB457 is a substituted benzamide with the affinity of 0.02 nmol·l⁻¹ for D2 and D3 dopamine receptors in vitro, which is significantly higher than that of [11C]raclopride (1–2 nmol·l⁻¹).13 This characteristic allows for examination of extrastriatal brain regions where D2-R densities are low. [11C]FLB457 was synthesized as described previously.23 The injected dose for PET1 and PET2 was 466 ± 16 and 465 ± 19 MBq, respectively. For technical reasons, information on specific activity related to anxiety levels, LSASanx was the outcome variable of main interest. In several cases, the time between clinical rating and PET examinations was extended up to several months, and in some instances the rating was performed by different psychiatrists before and after treatment. Therefore, only LSAS-SR scores were included in the analysis. PET1 was performed on average 13 ± 14 (mean ± s.d.) days before pre-treatment ratings, and the time between post-treatment ratings and PET 2 was 17 ± 15 days.

Table 1 Patient demographics

| Patient | Age (years) | Sex | Duration of disorder (years) | Family history | Pre LSAS score |
|---------|-------------|-----|-----------------------------|---------------|---------------|
| 1       | 23          | F   | 7                           | –             | 41            |
| 2       | 38          | M   | 31                          | +             | 71            |
| 3       | 23          | M   | 15                          | –             | 63            |
| 4       | 58          | F   | 45                          | –             | 72            |
| 5       | 37          | F   | 31                          | +             | 84            |
| 6       | 30          | F   | 19                          | +             | 43            |
| 7       | 26          | F   | 3                           |               | 41            |
| 8       | 35          | F   | 28                          | –             | 76            |
| 9       | 25          | M   | 10                          | +             | 44            |

Abbreviations: F, female; +, indicates at least one of parents affected; LSAS, Liebowitz Social Anxiety Scale; M, male.
specific activity was 1436 ± 2348 and 658 ± 583 GBq μmol⁻¹ for PET1 and PET2, and the mass of injected FLB 457 was 0.41 ± 0.3 and 0.58 ± 0.6 μg, respectively. The injected dose, specific activity and mass did not differ between pre- and posttreatment (P > 0.5, paired t-test), and importantly, there was no correlation between injected mass and either BPND or symptom change.

**PET examinations.** PET examinations were performed on a high-resolution research tomograph system (Siemens Molecular Imaging, Knoxville, TN, USA). Before the first PET examination, a plaster helmet was manufactured for each subject individually to reduce head movement during measurements. The time between PET1 and PET2 was 146 ± 23 days. Average time for injection was 12:24 for PET 1 and 11:53 for PET2. Before the emission, a 5-min transmission scan was performed to correct for attenuation and scatter. [11C]FLB 457 was injected in the antecubital vein as a bolus dose and radioactivity was measured for 87 min. For two subjects, the second examination was interrupted between 910 and 1416 s and 3361 and 3623 s, respectively. These intervals were excluded from the subsequent kinetic analysis. Images were reconstructed using the ordinary Poisson three-dimensional ordered subset expectation maximization including the point spread function algorithm, yielding an in-plane resolution of 1.5 mm at half-maximum at the center of field-of-view.

**Image analysis.** PET images were corrected for head movement using a frame-by-frame realignment procedure with each frame of the image serving as a reference to the next. T1 MR images were realigned to the anterior commissure – posterior commissure plane. Regions of interest (ROIs) were manually defined on the MRI for each subject individually, using Human Brain Atlas software. Regions chosen were amygdala, hippocampus and prefrontal cortices, based on their proposed role in SAD, and ROIs were defined using previously published guidelines. The prefrontal cortex was divided into dorsolateral, medial and orbitofrontal regions. Striatal regions were not evaluated, as the high affinity of [11C]FLB 457 does not allow for equilibrium within the frame of a PET experiment, thus preventing meaningful calculations of radioligand binding. MRIs were segmented into gray matter, white matter and cerebrospinal fluid, and coregistered to each of the two PET images using SPM5. The transformation parameters obtained were used to subsequently apply the ROIs on the dynamic PET images to generate time activity curves (TACs). For frontal cortical regions, only voxels belonging to the gray matter segment was included in the ROI. Also, partial volume effect correction using the Meltzer method was applied for these regions to avoid smearing effects from neighboring CSF voxels. Image processing was performed on SPM5 operating on Matlab R2007b (MathWorks, Natick, MA, USA).

BPND was calculated from the TACs using the simplified reference tissue model (SRTM), with cerebellum as reference. In this context, BPND represents the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue. The SRTM has previously been validated for [11C]FLB 457. Since we had no hypothesis of side differences in the involvement of dopaminergic neurotransmission in SAD, BPND for all regions was calculated...
using spatially averaged TACs for right and left sides in order to improve TAC statistics.

**Statistical analysis.** Changes in LSAS scores and D2-R BP<sub>ND</sub> were assessed using a paired t-test. Associations between D2-R BP<sub>ND</sub> and LSAS scores at baseline were calculated using partial correlations, controlling for age. The relationship between changes in regional D2-R binding and changes in LSAS<sub>anx</sub> scores was assessed using a repeated measures analysis of covariance, with time and region as within-subject factors and LSAS<sub>anx</sub> percent change as a covariate. Secondary analyses were performed for LSAS<sub>avoid</sub> and the two subscales combined. Subsequently, correlation coefficients were calculated between percent change in D2 BP<sub>ND</sub> and percent change in LSAS<sub>anx</sub> scores. In a post-hoc analysis, individuals were divided into responders (≥50% symptom reduction) and non-responders, and group differences in change in BP<sub>ND</sub> values were explored using a one-way analysis of variance. For all tests, results were considered significant at *P*<0.05. Statistical analysis was performed using PASW 18 (SPSS, Chicago, IL, USA).

### Results

**Changes in social anxiety levels and D2-R BP<sub>ND</sub>.** All patients improved after treatment, and the change in total LSAS scores as well as anxiety and avoidance subscales was statistically significant (Table 2). There was no difference in LSAS change between patients receiving group therapy and those treated via the internet, either for the whole scale or for subscales (*P*>0.74). At posttreatment, four (44%) participants no longer met diagnostic criteria for SAD. On a group level, the difference in D2-R binding pre- and posttreatment did not reach statistical significance for any of the regions, as assessed using a paired t-test (Table 2). However, the direction and degree of change showed a considerable interindividual variability, which enabled computation of meaningful correlations with symptom change.

**Associations between D2-R BP<sub>ND</sub> change and social anxiety change.** In the repeated measures analysis of covariance, significant effects for time and time *×* symptom score change were shown for LSAS<sub>anx</sub> (*F* = 7.61, *P* = 0.028 and *F* = 7.77, *P* = 0.027). In a subsequent region-by-region analysis, negative correlations between change in D2-R BP<sub>ND</sub> and LSAS<sub>anx</sub> change were shown for dorsolateral prefrontal cortex (*r* = −0.78, *P* = 0.013), medial prefrontal cortex (*r* = −0.82, *P* = 0.007) as well as for hippocampus (*r* = −0.81, *P* = 0.008; Figure 2). The correlations in medial prefrontal cortex and hippocampus survived Bonferroni correction (adjusted *P*-value < 0.01). In these regions, responders showed an increase in binding (5.0% and 9.5%, respectively, *n* = 4), whereas non-responders on average showed a decrease (−8.6% and −8.3%, *n* = 5). Despite few individuals in each group, this difference was significant for MFC (*P* = 0.003) and trend-level significant for hippocampus (*P* = 0.097). There was no significant effect of time or time *×* symptom change on the avoidance subscale. This difference of effects between subscales was also reflected in that when combining the two scales as covariate, trend-level effects were observed for time (F = 3.93, *P* = 0.088) and the interaction term for time *×* change (F = 3.74, *P* = 0.095).

**Pre- and posttreatment correlations between D2-R BP<sub>ND</sub> and social anxiety.** There was no correlation between D2-R BP<sub>ND</sub> and LSAS<sub>anx</sub> or LSAS<sub>avoid</sub> scores pre- or posttreatment, after controlling for age.

### Discussion

In this study, we assessed the role of the extrastriatal dopamine system in SAD, by examining changes in dopamine D2-R binding as a function of symptom change after CBT. Importantly, the aim of this study was not to examine the effects of psychological treatment on D2-R binding in SAD, as this would entail the use of a control condition. Instead, CBT was used as a tool to alter the disease state non-pharmacologically. Consequently, the association between change in symptom scores and changes in receptor binding was the primary outcome, rather than changes pre- and posttreatment on a group level. Accordingly, whereas the average difference between PET1 and PET2 was within the test-retest variability shown previously for [<sup>11</sup>C]FLB 457,*<sup>31</sup> the interindividual variability in change was sufficient for correlative analyses. Using a similar design, changes in D1-receptor binding was recently shown to be related to improvement in working memory capacity after working memory training,*<sup>32</sup> and we now the first time demonstrate a direct relationship between symptom reduction after
particular interest is the study by Morgan et al.,44 where D2-R binding in the medial temporal lobe as measured using $[^{11}\text{C}]$FLB 457. In the interpersonal domain, these personality traits can be viewed to indicate social submission as opposed to social dominance,40 and the results thus mirror research on rodents and non-human primates where dopaminergic neurotransmission has been linked to the dimension of dominance-submissive behavior.41–44 Of particular interest is the study by Morgan et al.,44 where D2-R binding in monkeys was shown to change as a function of hierarchical rank as the animals moved from individual to social housing. The observation of a relationship between change in D2-R binding and social anxiety symptoms is congruent with these lines of research and can be viewed as support for a suggested link between the dominant-submissive dimension of interpersonal behavior and SAD.45 The correlation was not significant for LSAS avoid, which may be explained by the more heterogeneous nature of avoidant behavior. For instance, reduced avoidance with maintained safety behaviors is not expected to yield less anxiety.21

SPECT studies have previously shown reduced dopamine D2-R binding in the striatum in 10 patients with SAD, as well as in a sample of 7 with comorbid OCD in comparison to control subjects.1,2 On the presynaptic side, lower dopamine transporter binding was demonstrated in 11 patients.3 In a more recent study using PET, no difference was shown in D2-R availability, either at baseline or after an amphetamine challenge, and there was also no difference in binding to the dopamine transporter ($n=15$, 12 and 12, respectively).4 However, none of these studies assessed dopamine receptors in extrastratal brain regions.

In brain activation studies, one of the most replicated findings is increased activation in amygdala in response to fearful social stimuli46–48 but notably, negative findings have also been reported.49,50 Other regions showing altered activation in SAD include hippocampal and prefrontal cortices.5,46,47,51–53 For the medial prefrontal cortex, a role specifically for monitoring social evaluation has been shown in SAD patients51,52 and this region is also implicated in fear extinction.54,55 Dopaminergic transmission in the hippocampus has shown to be involved in memory function in animal research as well as in molecular imaging studies.56–59 Taken together, the present findings of a correlation between dopaminergic function in hippocampus and prefrontal cortical regions may be related to the role of these regions in learning and social evaluation.

The primary limitation of this study is the small sample size. Although a total of 126 patients were included in the treatment study,13 for the present study we applied more strict inclusion criteria in order to avoid confounding effects on D2-R availability, for instance by the use of concomitant pharmacological treatment or nicotine. Furthermore, some patients were lost due to time constraints. Second, we cannot determine whether the changes in BP$_{ND}$ are due to changes in receptor density or apparent affinity, as these parameters cannot be dissociated based on a single PET measurement.30 Among the factors influencing apparent affinity, endogenous dopamine levels have shown to affect $[^{11}\text{C}]$FLB 457 binding,50–62 however, other studies have been negative.53,64 In rodents, where neurotransmitter levels are more accessible, increased DA release has been observed in response to stressful stimuli.65,66 Although studies employing multiple PET examinations with different specific activity of $[^{11}\text{C}]$FLB 457 have shown that receptor density accounts for most of the variance in BP$_{ND}$,67 it cannot be excluded that differences in endogenous dopamine levels could partly account for the associations observed, for instance reflecting higher DA reactivity during the examination procedure in patients with lesser improvement after treatment.

In conclusion, the results from this preliminary study indicate that plastic changes in the dopamine system may underlie reduced anxiety symptoms in SAD patients after treatment with CBT. The study supports a role for the dopamine system in SAD, and shows that intra-individual comparisons can be a promising approach in identifying brain biomarkers for psychiatric disorders.

**Conflict of interest**

The authors declare no conflict of interest.
Acknowledgements. The study was supported by Söderström Königstens Stiftelsen, The National Board of Health and Welfare, Stockholm County Council and Psykiatrifonden. The staff at the Karolinska PET Center and at the Internet Psychiatry Unit at the Karolinska University Hospital Huddinge are thankfully acknowledged.

1. Schreer FR, Liebowitz MR, Abi-Dargham A, Zee-Pone Y, Lin SH, Larelue M. Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry 2000; 157: 457–459.
2. Schreer FR, Martinez D, Abi-Dargham A, Zee-Pone Y, Simpson HB, Liebowitz MR et al. Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 2008; 25: 1–7.
3. Tilsonen J, Kulkka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997; 154: 239–242.
4. Schreer FR, Abi-Dargham A, Martinez D, Sifisteen M, Hwang D-R, Liebowitz MR et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety 2009; 26: 411–418.
5. Freitas-Ferrari MC, Hallak JEC, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas et al. Radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 2009; 50: 508–510.
6. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T et al. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 585–586.
7. Farde L, Hall H, Paul S, Halldin C. Variability in D2 dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 1995; 20: 200–208.
8. Fesdorf IF, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001; 21: 311–324.
9. Jarstad-Stein EC, Heimberg RG. Social phobia: an update on treatment. Psychiatr Clin North Am 2009; 32: 641–663.
10. Lehto SM, Tolmunen T, Joensuu M, Saarinen PI, Valkonen-Korhonen M, Vanninen R et al. Changes in midbrain seroton receptor transporter availability in atypically depressed subjects after one year of psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 2033–2037.
11. Karlsson H, Hirvonen J, Kajander J, Markkula J, Rasi-Hakala H, Salminen JK et al. Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol Med 2010; 40: 523–528.
12. Hirvonen J, Hetala J, Kajander J, Markkula J, Rasi-Hakala H, Salminen J et al. Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/D3 receptors in major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol 2010; 24: 1329–1336.
13. Heimberg RG, Becker RE. Cognitive-Behavioral Group Therapy for Social Phobia: Basic Mechanisms and Clinical Strategies. Guilford Press: New York, 2002.
14. Haldin C, Farde L, Hogberg T, Mohn E, Hall H, Suhrada T et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36: 1275–1281.
15. Varonne A, Spholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OPI-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009; 36: 1393–1394.
16. Hedman E, Andersson G, Ljotsen B, Andersson E, Ruck C, Mortberg E et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. J Consult Clin Psychol 1999; 67: 156–162.
17. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR et al. Antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors with major depressive disorder. J Nucl Med 1995; 36: 1395–1396.
18. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. J Psychopathol Behav Assess 1995; 17: 339–354.
19. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. J Psychopathol Behav Assess 1995; 17: 199–212.
20. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR et al. Antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/D3 receptors with major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol 2010; 24: 1329–1336.
21. Heimberg RG, Becker RE. Cognitive-Behavioral Group Therapy for Social Phobia: Basic Mechanisms and Clinical Strategies. Guilford Press: New York, 2002.
22. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. J Psychopathol Behav Assess 1995; 17: 239–242.
23. Schreer FR, Abi-Dargham A, Martinez D, Sifisteen M, Hwang D-R, Liebowitz MR et al. Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder. Depress Anxiety 2009; 26: 411–418.
24. Freitas-Ferrari MC, Hallak JEC, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas et al. Radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 2009; 50: 508–510.
25. Halldin C, Farde L, Hogberg T, Mohn E, Hall H, Suhrada T et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36: 1275–1281.
26. Varonne A, Spholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OPI-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009; 36: 1393–1394.
27. Hedman E, Andersson G, Ljotsen B, Andersson E, Ruck C, Mortberg E et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy. Therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS ONE 2011; 6: e18001.
28. APA. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Pub: Washington, DC, 2000.
29. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22–33; quiz 34–57.
30. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneider FR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999; 29: 199–212.
31. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB et al. The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered forms. Psychol Med 2001; 31: 1025–1035.
32. Andersson G, Carbring P, Holmstrom A, Spathan E, Furmark T, Nilsson-Hjertf E et al. Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial. J Consult Clin Psychol 2006; 74: 677–686.
33. Clark DM, Wells A. A Cognitive Model of Social Phobia. In: Heimberg RG, Leibowitz M, Hope DA, Schneider FR, (eds). Chapter 4. Guilford press: New York, 1995.
34. Rapo RM, Heimberg RG. A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther 1997; 35: 741–756.
35. Sandel J, Langner O, Larsen P, Daffe F, Vaubre F, Demphel S et al. Improved specific radiolabeling of the PET radioligand [11C]FLB 457 by use of the GE Medical Systems PETtrace Microlab. J Labeled Comp Radiopharm 2000; 43: 331–338.
36. Montgomery AJ, Thelmaens K, Mehta MA, Turkheimer F, Mustaficov S, Grasby PM. Correction of head movement on PET studies: comparison of methods. J Nucl Med 2006; 47: 1936–1944.
52. Blair KS, Geraci M, Holton N, Otero M, DeVido J, Majestic C et al. Social norm processing in adult social phobia: atypically increased ventromedial frontal cortex responsiveness to unintentional (embarrassing) transgressions. Am J Psychiatry 2010; 167: 1526–1532.

53. Goldin PR, Manber T, Hakimi S, Carli T, Gross JJ. Neural bases of social anxiety disorder: emotional reactivity and cognitive regulation during social and physical threat. Arch Gen Psychiatry 2009; 66: 170–180.

54. Sotres-Bayon F, Cain CK, LeDoux JE. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol Psychiatry 2006; 60: 329–336.

55. Milad MR, Quirk GJ. Neurons in medial prefrontal cortex signal memory for fear extinction. Nature 2002; 420: 70–74.

56. Frey U, Schroeder H, Matthies H. Dopaminergic antagonists prevent long-term maintenance of posttetanic LTP in the CA1 region of rat hippocampal slices. Brain Res 1990; 522: 69–75.

57. Takahashi H, Kato M, Hayashi M, Okubo Y, Takano A, Ito H et al. Memory and frontal lobe functions: possible relations with dopamine D2 receptors in the hippocampus. Neuroimage 2007; 34: 1643–1649.

58. Omegaki H, Munoz J, Meyer RC, Spangler EL, Yoshimura J, Ikari H et al. Involvement of dopamine D2 receptors in complex maze learning and acetylcholine release in ventral hippocampus of rats. Neuroscience 2001; 103: 27–33.

59. Takahashi H, Kato M, Takano H, Arakawa R, Okumura M, Otsuka T et al. Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. J Neurosci 2008; 28: 12032–12038.

60. Aalto S, Bruck A, Laine M, Nagren K, Rimme JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005; 25: 2471–2477.

61. Narendran R, Frankie WG, Mason NS, Rabiner EA, Gunn RN, Searle GE et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse 2009; 63: 447–461.

62. Montgomery AJ, Asselin MC, Farde L, Grasby PM. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab 2006; 27: 378–392.

63. Aalto S, Hinronen J, Kaasinen V, Hagelberg N, Kajander J, Nagren K et al. The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 2009; 36: 475–483.

64. Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K. Effect of endogenous dopamine on endogenous dopamine on extrastriatal [11C]FLB 457 binding measured by PET. Synapse 2001; 41: 87–95.

65. Blanc G, Herve D, Simon H, Liszczepawski A, Glowinski J, Tassin JP. Response to stress of mesocortico-frontal dopaminergic neurones in rats after long-term isolation. Nature 1989; 284: 265–267.

66. Bowling SL, Rowlett JK, Bardo MT. The effect of environmental enrichment on amphetamine-stimulated locomotor activity, dopamine synthesis and dopamine release. Neuropharmacology 1993; 32: 885–893.

67. Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 2004; 22: 794–803.